
CorMedix (CRMD) Stock Forecast & Price Target
CorMedix (CRMD) Analyst Ratings
Bulls say
Cormedix is improving its financial position by reiterating its revenue guidance and setting a higher EBITDA guidance for the current fiscal year, as well as expecting potential upside from new products and a potential label expansion for Rezzayo. The company's strong financial results and potential for sustained growth make it an attractive investment opportunity for a financial analyst. Additionally, the company is focused on sustainability and aligning with sustainable finance principles, which could further bolster its long-term prospects. However, there are risks involved with regulatory and commercial development, potential pricing pressure, and competition that could impact the company's rating and stock price.
Bears say
Cormedix is facing challenges in commercializing its product, DefenCath, in the highly competitive market for life-threatening diseases and conditions. While the company has potential upcoming catalysts such as the commercial performance of DefenCath and NDA filing for Rezzayo, there are significant risks to its rating and price target, including regulatory and competition risks. With concentration risk on one anchor customer and potential pricing pressure, and a limited track record in the biopharmaceutical industry, Cormedix's stock outlook appears negative.
This aggregate rating is based on analysts' research of CorMedix and is not a guaranteed prediction by Public.com or investment advice.
CorMedix (CRMD) Analyst Forecast & Price Prediction
Start investing in CorMedix (CRMD)
Order type
Buy in
Order amount
Est. shares
0 shares